Switch to:
GuruFocus has detected 1 Warning Sign with Biomarin Pharmaceutical Inc $BMRN.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
Biomarin Pharmaceutical Inc (NAS:BMRN)
Enterprise Value
$15,719 Mil (As of Today)

Think of enterprise value as the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.

EV/EBIT ratio is calculated as enterprise value divided by its EBIT. As of today, Biomarin Pharmaceutical Inc's enterprise value is $15,719 Mil. Biomarin Pharmaceutical Inc's earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Mar. 2017 was $-734 Mil. Therefore, Biomarin Pharmaceutical Inc's EV/EBIT ratio for today is -21.41.

EV/EBITDA ratio is calculated as enterprise value divided by its EBITDA. As of today, Biomarin Pharmaceutical Inc's enterprise value is $15,719 Mil. Biomarin Pharmaceutical Inc's earnings before depreciation and amortization for the trailing twelve months (TTM) ended in Mar. 2017 was $-612 Mil. Therefore, Biomarin Pharmaceutical Inc's EV/EBITDA ratio for today is -25.69.

EV/Revenue ratio is calculated as enterprise value divided by its Revenue. As of today, Biomarin Pharmaceutical Inc's enterprise value is $15,719 Mil. Biomarin Pharmaceutical Inc's revenue for the trailing twelve months (TTM) ended in Mar. 2017 was $1,184 Mil. Therefore, Biomarin Pharmaceutical Inc's EV/Revenue ratio for today is 13.28.


Definition

Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.

Biomarin Pharmaceutical Inc's Enterprise Value for the fiscal year that ended in Dec. 2016 is calculated as

Enterprise Value (A: Dec. 2016 )
=Market Cap+Preferred Stock+Long-Term Debt & Capital Lease Obligation
=14302.326+0+660.761
+Current Portion of Long-Term Debt+Minority Interest-Cash, Cash Equivalents, Marketable Securities
+22.478+0-789.677
=14,196

Biomarin Pharmaceutical Inc's Enterprise Value for the quarter that ended in Mar. 2017 is calculated as

Enterprise Value (Q: Mar. 2017 )
=Market Cap+Preferred Stock+Long-Term Debt & Capital Lease Obligation
=15211.3962+0+668.437
+Current Portion of Long-Term Debt+Minority Interest-Cash, Cash Equivalents, Marketable Securities
+22.495+0-678.055
=15,224

* All numbers are in millions except for per share data and ratio. All numbers are in their local exchange's currency.


Explanation

When an investor buy a company, the investor needs to pay not only the common shares, he/she also needs to pay the shareholders of Preferred Stocks. He also assumes the debt of the company, and receives the cash on the company's balance sheet.

If a company has more cash than debt, the investor actually pays less than the Market Cap because he immediately owns the cash once the transaction goes through.

The market value of Preferred Stock needs to be added to the market value of common stocks in the calculation of enterprise value.

For the companies with the same Market Cap, the smaller the Enterprise Value is, the cheaper the company is.

Enterprise Value can be negative when the company's net cash is more than its Market Cap. In this case the investor is basically getting the company for free and get paid for that.

1. EV/EBIT ratio is calculated as enterprise value divided by its EBIT.

Biomarin Pharmaceutical Inc's EV/EBIT for today is

Biomarin Pharmaceutical Inc's current Enterprise Value is $15,719 Mil.
Biomarin Pharmaceutical Inc's Earnings Before Interest and Taxes (EBIT) for the trailing twelve months (TTM) ended in Mar. 2017 was -573.001 (Jun. 2016 ) + -56.833 (Sep. 2016 ) + -82.434 (Dec. 2016 ) + -21.887 (Mar. 2017 ) = $-734 Mil.

2. EV/EBITDA ratio is calculated as enterprise value divided by its EBITDA.

Biomarin Pharmaceutical Inc's EV/EBITDA for today is:

Biomarin Pharmaceutical Inc's current Enterprise Value is $15,719 Mil.
Biomarin Pharmaceutical Inc's Earnings Before Depreciation and Amortization for the trailing twelve months (TTM) ended in Mar. 2017 was -518.587 (Jun. 2016 ) + -28.524 (Sep. 2016 ) + -62.327 (Dec. 2016 ) + -2.475 (Mar. 2017 ) = $-612 Mil.

3. EV/Revenue ratio is calculated as enterprise value divided by its Revenue.

Biomarin Pharmaceutical Inc's EV/Revenue for today is:

EV/Revenue ratio=Enterprise Value (Today)/Revenue (TTM)
=15718.727/1183.863
=13.28

Biomarin Pharmaceutical Inc's current Enterprise Value is $15,719 Mil.
Biomarin Pharmaceutical Inc's Earnings Before Depreciation and Amortization for the trailing twelve months (TTM) ended in Mar. 2017 was 300.131 (Jun. 2016 ) + 279.896 (Sep. 2016 ) + 300.091 (Dec. 2016 ) + 303.745 (Mar. 2017 ) = $1,184 Mil.

* All numbers are in millions except for per share data and ratio. All numbers are in their local exchange's currency.


Related Terms

Market Cap, Preferred Stock, Long-Term Debt & Capital Lease Obligation, Cash, Cash Equivalents, Marketable Securities, Current Portion of Long-Term Debt


Historical Data

* All numbers are in millions except for per share data and ratio. All numbers are in their local exchange's currency.

Biomarin Pharmaceutical Inc Annual Data

Dec07Dec08Dec09Dec10Dec11Dec12Dec13Dec14Dec15Dec16
ev 3,3491,7852,0953,0834,1006,0909,95813,17316,99214,196

Biomarin Pharmaceutical Inc Quarterly Data

Dec14Mar15Jun15Sep15Dec15Mar16Jun16Sep16Dec16Mar17
ev 13,17319,67221,99617,02316,99213,59212,87015,52614,19615,224
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}
FEEDBACK